Literature DB >> 11106352

Neurofibromatosis type 2.

D G Evans1, M Sainio, M E Baser.   

Abstract

Neurofibromatosis type 2 is an often devastating autosomal dominant disorder which, until relatively recently, was confused with its more common namesake neurofibromatosis type 1. Subjects who inherit a mutated allele of the NF2 gene inevitably develop schwannomas, affecting particularly the superior vestibular branch of the 8th cranial nerve, usually bilaterally. Meningiomas and other benign central nervous system tumours such as ependymomas are other common features. Much of the morbidity from these tumours results from their treatment. It is now possible to identify the NF2 mutation in most families, although about 20% of apparently sporadic cases are actually mosaic for their mutation. As a classical tumour suppressor, inactivation of the NF2 gene product, merlin/schwannomin, leads to the development of both NF2 associated and sporadic tumours. Merlin/schwannomin associates with proteins at the cell cytoskeleton near the plasma membrane and it inhibits cell proliferation, adhesion, and migration.

Entities:  

Mesh:

Year:  2000        PMID: 11106352      PMCID: PMC1734496          DOI: 10.1136/jmg.37.12.897

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  75 in total

1.  Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading.

Authors:  D H Gutmann; L Sherman; L Seftor; C Haipek; K Hoang Lu; M Hendrix
Journal:  Hum Mol Genet       Date:  1999-02       Impact factor: 6.150

2.  A clinical study of type 1 neurofibromatosis in north west England.

Authors:  J M McGaughran; D I Harris; D Donnai; D Teare; R MacLeod; R Westerbeek; H Kingston; M Super; R Harris; D G Evans
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

3.  Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma.

Authors:  D G Evans; R Lye; W Neary; G Black; T Strachan; A Wallace; R T Ramsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 4.  Regulation of cortical structure by the ezrin-radixin-moesin protein family.

Authors:  A Bretscher
Journal:  Curr Opin Cell Biol       Date:  1999-02       Impact factor: 8.382

5.  Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.

Authors:  D G Evans; A J Wallace; C L Wu; L Trueman; R T Ramsden; T Strachan
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

6.  Long-term outcomes after radiosurgery for acoustic neuromas.

Authors:  D Kondziolka; L D Lunsford; M R McLaughlin; J C Flickinger
Journal:  N Engl J Med       Date:  1998-11-12       Impact factor: 91.245

7.  NF2 gene in neurofibromatosis type 2 patients.

Authors:  J Zucman-Rossi; P Legoix; H Der Sarkissian; G Cheret; F Sor; A Bernardi; L Cazes; S Giraud; E Ollagnon; G Lenoir; G Thomas
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

8.  Mosaicism in sporadic neurofibromatosis 2 patients.

Authors:  L Kluwe; V F Mautner
Journal:  Hum Mol Genet       Date:  1998-12       Impact factor: 6.150

9.  Hearing preservation in neurofibromatosis type 2.

Authors:  W H Slattery; D E Brackmann; W Hitselberger
Journal:  Am J Otol       Date:  1998-09

10.  Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin.

Authors:  M Grönholm; M Sainio; F Zhao; L Heiska; A Vaheri; O Carpén
Journal:  J Cell Sci       Date:  1999-03       Impact factor: 5.285

View more
  30 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  Cutaneous plexiform schwannomas in a patient with neurofibromatosis type 2.

Authors:  Joo Yeon Ko; Ji Eun Kim; Young Hoon Kim; Young Suck Ro
Journal:  Ann Dermatol       Date:  2009-11-30       Impact factor: 1.444

Review 3.  News on the genetics, epidemiology, medical care and translational research of Schwannomas.

Authors:  C O Hanemann; D G Evans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

Review 4.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

5.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

6.  The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.

Authors:  Guang-Hui Xiao; Ryan Gallagher; Justin Shetler; Kristine Skele; Deborah A Altomare; Richard G Pestell; Suresh Jhanwar; Joseph R Testa
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  Anaesthetic management of a child with neurofibromatosis type 2 for multiple tumour decompressions.

Authors:  Geetha Lakshiminarasimhaiah; Aniruddha Thekkatte Jagannatha; Kulyadi Raghavendra Pai; Ravi Gopal Varma; Alangar Satyaranjandas Hegde
Journal:  J Clin Diagn Res       Date:  2013-12-15

Review 8.  The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

Authors:  Bin Zhao; Qun-Ying Lei; Kun-Liang Guan
Journal:  Curr Opin Cell Biol       Date:  2008-11-18       Impact factor: 8.382

9.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

Review 10.  The genetic and epigenetic basis of ependymoma.

Authors:  Stephen C Mack; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2009-06-18       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.